Abstract
Aim:
In the present study we report the clinical outcome of 27 patients with refractory or relapsed Hodgkin's lymphoma (HL) undergoing autologous peripheral stem-cell transplantation (ASCT).
Methods:
On transplant, 18 patients had sensitive disease (SD) and 9 resistant disease (RD). The median time between diagnosis and ASCT was 18 months (range, 7 to 96 months). The conditioning consisted of BEAM regimen.
Results:
The 100-day mortality rate was 3%. Three months after transplant, 12 patients transplanted with SD were in complete remission (CR) and only one of the 9 patients transplanted with RD achieved CR. Overall survival and disease-free survival after 3 years were 68% and 60%, respectively.
Conclusion:
the present results confirm the efficacy and safety of the ASCT in refractory or relapsed HL patients with SD. Other strategies should be investigated for patients with RD.
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carmustine / administration & dosage
-
Carmustine / therapeutic use
-
Child
-
Cytarabine / administration & dosage
-
Cytarabine / therapeutic use
-
Data Interpretation, Statistical
-
Disease-Free Survival
-
Drug Resistance, Neoplasm
-
Etoposide / administration & dosage
-
Etoposide / therapeutic use
-
Follow-Up Studies
-
Hodgkin Disease / drug therapy*
-
Hodgkin Disease / mortality
-
Hodgkin Disease / pathology
-
Hodgkin Disease / therapy*
-
Humans
-
Melphalan / administration & dosage
-
Melphalan / therapeutic use
-
Neoplasm Staging
-
Peripheral Blood Stem Cell Transplantation* / adverse effects
-
Recurrence
-
Remission Induction
-
Time Factors
-
Transplantation Conditioning*
-
Transplantation, Autologous
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Cytarabine
-
Etoposide
-
Melphalan
-
Carmustine